Figure 1: Streptozotocin injection induced type 1 diabetic rats exhibited impaired glucose tolerance and reduced myocardial AMPK/PGC-1α and SIRT3 signaling. | Scientific Reports

Figure 1: Streptozotocin injection induced type 1 diabetic rats exhibited impaired glucose tolerance and reduced myocardial AMPK/PGC-1α and SIRT3 signaling.

From: Melatonin ameliorates myocardial ischemia/reperfusion injury in type 1 diabetic rats by preserving mitochondrial function: role of AMPK-PGC-1α-SIRT3 signaling

Figure 1

(a) Non-fasting plasma glucose of control rats and type 1 diabetic rats after 7 days of streptozotocin injection. (b) Fasting plasma glucose of control rats and type 1 diabetic rats after 7 days of streptozotocin injection. (c) Intraperitoneal glucose tolerance test after 7 days of streptozotocin injection. (d) Oral glucose tolerance test (OGTT) after 7 days of streptozotocin injection. (e) Representative blots. Myocardial p-AMPK, PGC-1α, SIRT3 and SOD2 expressions were evaluated after 1 month of streptozotocin injection. (f) p-AMPK/AMPK ratio. (g) SIRT3 expression. (h) PGC-1α expression. (i) SOD2 expression. (j) Representative myocardial immunohistochemistry images of PGC-1α, SIRT3 and SOD2 (120×, bar = 400 μm). The depicted data are the means ± SEM, n = 6/group. **P < 0.01 vs. the Control group. T1D, type 1 diabetes. PG, plasma glucose. IPGTT, intraperitoneal glucose tolerance test. OGTT, oral glucose tolerance test.

Back to article page